130 related articles for article (PubMed ID: 1434792)
1. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
Leukemia; 1992 Nov; 6(11):1107-12. PubMed ID: 1434792
[TBL] [Abstract][Full Text] [Related]
2. Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.
van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
Leukemia; 1994 Sep; 8(9):1503-9. PubMed ID: 8090030
[TBL] [Abstract][Full Text] [Related]
3. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
van Denderen J; Hermans A; Meeuwsen T; Troelstra C; Zegers N; Boersma W; Grosveld G; van Ewijk W
J Exp Med; 1989 Jan; 169(1):87-98. PubMed ID: 2462613
[TBL] [Abstract][Full Text] [Related]
4. Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
van Denderen J; van der Plas D; Meeuwsen T; Zegers N; Boersma W; Grosveld G; van Ewijk W
Blood; 1990 Jul; 76(1):136-41. PubMed ID: 2194587
[TBL] [Abstract][Full Text] [Related]
5. Detection of tumor-specific antigens in Philadelphia chromosome positive leukemias.
van Denderen J; ten Hacken P; Berendes P; van Ewijk W
Leuk Lymphoma; 1993; 11 Suppl 1():29-32. PubMed ID: 7504546
[TBL] [Abstract][Full Text] [Related]
6. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2.
Iwata S; Mizutani S; Nakazawa S; Yata J
Leukemia; 1994 Oct; 8(10):1696-702. PubMed ID: 7934165
[TBL] [Abstract][Full Text] [Related]
9. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
10. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
[TBL] [Abstract][Full Text] [Related]
11. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Soekarman D; van Denderen J; Hoefsloot L; Moret M; Meeuwsen T; van Baal J; Hagemeijer A; Grosveld G
Leukemia; 1990 Jun; 4(6):397-403. PubMed ID: 2193202
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
13. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.
Mills KI; Sproul AM; Leibowitz D; Burnett AK
Leukemia; 1991 Nov; 5(11):937-41. PubMed ID: 1961034
[TBL] [Abstract][Full Text] [Related]
14. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelocytic leukemia--Part I: History, clinical presentation, and molecular biology.
Randolph TR
Clin Lab Sci; 2005; 18(1):38-48. PubMed ID: 15747785
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
17. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Barrett J; Guimaraes A; Cullis J; Goldman JM
Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
[TBL] [Abstract][Full Text] [Related]
18. [Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].
Artigas CG; Melo A; Roa JC; Páez E; Vittini C; Arriagada M; González L; Pflaumer E; Roa I
Rev Med Chil; 2002 Jun; 130(6):623-30. PubMed ID: 12194684
[TBL] [Abstract][Full Text] [Related]
19. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
20. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
